Abstract:
:TP53 is the most frequently mutated gene in breast cancer, but its role in survival is confounded by different studies concluding that TP53 mutations are associated with negative, neutral, or positive outcomes. Closer examination showed that many studies were limited by factors such as imprecise methods to detect TP53 mutations and small cohorts that combined patients treated with drugs having very different mechanisms of action. When only studies of patients receiving the same treatment(s) were compared, they tended to agree. These analyses reveal a role for TP53 in response to different treatments as complex as its different biological activities. We discuss studies that have assessed the role of TP53 mutations in breast cancer treatment and limitations in interpreting reported results.
journal_name
Trends Cancerjournal_title
Trends in cancerauthors
Shahbandi A,Nguyen HD,Jackson JGdoi
10.1016/j.trecan.2020.01.007subject
Has Abstractpub_date
2020-02-01 00:00:00pages
98-110issue
2eissn
2405-8033issn
2405-8025pii
S2405-8033(20)30020-0journal_volume
6pub_type
杂志文章,评审相关文献
Trends in Cancer文献大全abstract::The 'mild' cold stress caused by standard sub-thermoneutral housing temperatures used for laboratory mice in research institutes is sufficient to significantly bias conclusions drawn from murine models of several human diseases. We review the data leading to this conclusion, discuss the implications for research and s...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2016.03.005
更新日期:2016-04-01 00:00:00
abstract::Given the implication of aberrant RAS-extracellular signal-regulated kinase (ERK) signaling in the development of a large number of tumor types, this route is under intense scrutiny to identify new anticancer drugs. Most avenues in that direction have been primarily focused on the inhibition of the catalytic activity ...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2018.07.002
更新日期:2018-09-01 00:00:00
abstract::In recognition of the enormous potential of immunotherapies against cancer, research into the interactions between tumor and immune cells has accelerated, leading to the recent FDA approval of several drugs that reduce cancer progression. Numerous cellular and molecular interactions have been identified by which immun...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2015.12.003
更新日期:2016-01-01 00:00:00
abstract::Alternative splicing (AS) has many important roles in the pathogenesis of leukemia. Recent papers suggest that one of its key aspects is exclusion of 3'-terminal exons in favor of premature termination using intronic polyadenylation signals. This process generates leukemia suppressor isoforms with truncated C termini ...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2018.10.005
更新日期:2018-12-01 00:00:00
abstract::Ibrutinib resistance, as a result of coordinated rewiring of signaling networks and enforced tumor microenvironment (TME)-lymphoma interactions, drives unrestrained proliferation and disease progression. To combat resistance mechanisms, we must identify the compensatory resistance pathways and the central modulators o...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2018.01.004
更新日期:2018-03-01 00:00:00
abstract::Innate lymphoid cells (ILCs) fulfill important protective and reparative functions, and have thus been implicated in the maintenance of tissue homeostasis. Dysregulation of their activation is associated with several autoimmune and inflammatory diseases. The current literature on the role of ILCs in cancer is limited ...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2017.03.008
更新日期:2017-05-01 00:00:00
abstract::For millenia, plants have been a major source of medications against human and animal diseases. In the case of anticancer agents, a significant number of current agents can trace their source back to nominally plant secondary metabolites, with examples being taxol, vinca alkaloids, camptothecin (CPT), and their modifi...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2018.08.002
更新日期:2018-10-01 00:00:00
abstract::Fusobacterium nucleatum is an oral bacterium associated with colorectal cancer (CRC) proliferation, chemoresistance, inflammation, metastasis, and now DNA damage. While controlling F. nucleatum through antibiotics could reduce cancer severity, this article proposes additional strategies to block Fusobacterium-host int...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2020.11.006
更新日期:2020-12-09 00:00:00
abstract::Dynamic changes in the colorectal cancer (CRC) signalome and tumor genetic heterogeneity underlie acquired drug resistance. Improving treatment-related decisions is facilitated by an emerging consensus in the classification of tumor subtypes as well as by real-time monitoring of predictive biomarkers in circulating tu...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2017.01.003
更新日期:2017-03-01 00:00:00
abstract::The movement toward precision medicine with targeted therapeutics for cancer treatment has been hindered by both innate and acquired resistance. Understanding the molecular wiring and plasticity of oncogenic signaling networks is essential to the development of therapeutic strategies to avoid or overcome resistance. T...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2016.03.008
更新日期:2016-05-01 00:00:00
abstract::Curative therapy for cancer patients with advanced-stage disease remains elusive. While rare outlier responses to anticancer therapies exist, barriers limit our understanding of the molecular and genetic basis of such profound, life-altering responses. Here, we describe how phenotype-to-genotype studies are elucidatin...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2017.11.004
更新日期:2018-01-01 00:00:00
abstract::Cancer immunotherapy has recently emerged as a forefront strategy to fight cancer. Key players in antitumor responses are CD8+ cytolytic T lymphocytes (CTLs) that can detect tumor cells that carry antigens, in other words, small peptides bound to surface major histocompatibility complex (MHC) class I molecules. The su...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2017.07.007
更新日期:2017-10-01 00:00:00
abstract::The identification of STING as a key cytoplasmic innate recognition molecule for DNA viruses whose function is lost in a variety of cancers has coincided with the approval of IMLYGIC for metastatic melanoma. This represents the first replication competent viral therapy approved for the treatment of any cancer in the U...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2016.01.002
更新日期:2016-02-01 00:00:00
abstract::The molecular basis for the clinical heterogeneity observed in patients with malignant rhabdoid tumors is unknown. Recently, two reports revealed molecular inter-tumor heterogeneity in teratoid/rhabdoid tumors (ATRTs) and extra-cranial MRTs (ecMRTs) using genomic, transcriptomic and epigenomic profiling. Distinct mole...
journal_title:Trends in cancer
pub_type: 评论,杂志文章
doi:10.1016/j.trecan.2016.04.003
更新日期:2016-05-01 00:00:00
abstract::Tumor heterogeneity is a large conundrum in cancer medicine, making most therapeutic interventions palliative rather than curative. Here we discuss the implications of how molecularly targeted therapies in solid malignancies that promote limited cancer cell death may in fact make tumors more heterogeneous, increase ag...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2020.01.010
更新日期:2020-04-01 00:00:00
abstract::The tumor microenvironment has an essential role in defining tumor malignancy, since it can either promote or prevent tumor initiation and subsequent progression and metastatic dissemination. Recent studies demonstrate that highly aggressive cancer cells display a high degree of metabolic plasticity paralleled by the ...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2016.11.001
更新日期:2016-12-01 00:00:00
abstract::Prediction of long-term outcomes from short-term measurements remains a fundamental challenge. Quantitative assessment of signaling dynamics, and the resulting transcriptomic and proteomic responses, has yielded fundamental insights into cellular outcomes. However, the utility of these measurements is limited by their...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2020.12.008
更新日期:2021-01-12 00:00:00
abstract::Precision medicine requires appropriate application of genomics in clinical practice. In cancer, we have witnessed practice-changing examples of how genomic knowledge is translated into more tailored and effective therapies. The next opportunity is to embed cancer genomics in clinical context so that patient-centric l...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2015.07.010
更新日期:2015-09-01 00:00:00
abstract::Mitochondria play an essential role in cellular metabolism, generation of reactive oxygen species (ROS), and the initiation of apoptosis. These properties enable mitochondria to be crucial integrators in the pathways of tumorigenesis. An open question is to what extent variation in the mitochondrial genome (mtDNA) con...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2020.08.004
更新日期:2020-12-01 00:00:00
abstract::Regular exercise reduces the risk of cancer. One potential mechanism for this efficacy is improved antitumor immunity. This is an important issue because evading immune destruction is a hallmark of cancer and immunotherapy is reshaping cancer treatment. Here we review recent developments reported by Wennerberg et al.,...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2020.12.003
更新日期:2021-02-01 00:00:00
abstract::Immuno-oncology has gained momentum thanks to the success of strategies aimed at enhancing immune-mediated antitumor response. The field of immunotherapeutic transport oncophysics investigates the physical processes that drive cancer immunotherapies. This review discusses three main aspects that determine the outcome ...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2019.11.008
更新日期:2020-01-01 00:00:00
abstract::Dendritic cells (DCs) are key orchestrators of immune responses. A specific DC subset, conventional type 1 DCs (cDC1s), has been recently associated with human cancer patient survival and, in preclinical models, is critical for the spontaneous rejection of immunogenic cancers and for the success of T cell-based immuno...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2018.09.001
更新日期:2018-11-01 00:00:00
abstract::Dysregulation of the PI3K/PTEN pathway is a frequent event in cancer, and PIK3CA and PTEN are the most commonly mutated genes after TP53. PIK3R1 is the predominant regulatory isoform of PI3K. PIK3R2 is an ubiquitous isoform that has been so far overlooked, but data from The Cancer Genome Atlas shows that increased exp...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2019.02.009
更新日期:2019-04-01 00:00:00
abstract::Neutrophil extracellular traps (NETs) have emerged as significant contributors to cancer-associated pathologies such as metastasis, thrombosis, and organ dysfunction in preclinical models. We review recent discoveries of the involvement of NETs in human cancers and suggest tumor-induced NET formation as an interesting...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2016.10.012
更新日期:2016-11-01 00:00:00
abstract::Pancreatic ductal adenocarcinoma (PDAC) represents a major global health problem that causes over 200000 deaths each year worldwide. The disease is highly resistant to cytotoxic and targeted therapies and the average survival is less than 12 months. This situation prompted Alessandro Carugo and Giulio Draetta to devel...
journal_title:Trends in cancer
pub_type: 评论,杂志文章
doi:10.1016/j.trecan.2016.07.002
更新日期:2016-08-01 00:00:00
abstract::In this commentary, we review the timeline of clinical trials and regulatory actions of approved immune checkpoint inhibitors for small cell lung cancer, discuss challenges faced by regulatory agencies, and highlight paradoxical lessons that emerge. Accelerated approvals may fail to expedite drugs to market in this se...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2020.05.014
更新日期:2020-09-01 00:00:00
abstract::The pace of genomic and immunological breakthroughs in oncology is accelerating, making it likely that large randomized trials will increasingly become outdated before their completion. Traditional clinical research/practice paradigms must adapt to the reality unveiled by genomics, especially the need for customized d...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2017.12.004
更新日期:2018-02-01 00:00:00
abstract::Dicer-deficient cancers have poor prognoses, which is linked to the degradation of tumour-suppressing miRNA precursors by the Translin-Trax (Tn-Tx) ribonuclease. Inhibition of Tn-Tx potentially offers a new therapeutic intervention point. However, Tn-Tx functions in an array of biological processes, and here we consid...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2020.02.014
更新日期:2020-06-01 00:00:00
abstract::The regulation of immune responses by tumors is central to their survival. By diminishing the production of interferon (IFN) and other inflammatory mediators, tumors enhance immune evasion. Responses initiated by nucleic acid sensors and triggered by dysregulated RNA transcription and cytoplasmic DNA undergo down-modu...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2019.03.004
更新日期:2019-05-01 00:00:00
abstract::The p90 ribosomal S6 kinase family (RSK1-4) is a group of highly conserved Ser/Thr kinases that act as downstream effectors of the Ras/Raf/MEK/ERK signaling pathway. The RSKs phosphorylate a range of substrates involved in transcription, translation, cell cycle regulation, and cell survival. Although the RSKs have a h...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2017.03.004
更新日期:2017-04-01 00:00:00